Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Start Date
10/1/2023
Completion Date
9/1/2026
Summary
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There are currently three FDA-approved treatments for HS, including adalimumab, secukinumab, and bimekizumab, each with only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Fecal Microbiota - lyophilized
Placebo drug
Conditions
Locations
University of Minnesota
Minneapolis, Minnesota 55414
United States